In the news
Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.
Ann Arbor, MI and Salt Lake City, UT (April, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, and XCR Diagnostics, a sample-to-result systems company focused on actionable near patient results in 10 minutes or less, have announced today a chemistry license partnership to develop and implement three XCR® assays...
NeuMoDx™ Announces Completion of Series B Financing Funds Product Development for High Throughput Molecular Diagnostic Platform Ann Arbor, Michigan (March 26, 2014) – NeuMoDx™ Molecular, Inc., a privately held diagnostics company developing a new platform for high throughput, low cost molecular testing, today announced completion of its Series B financing. Pfizer Ventures led the $21 million...
Ann Arbor, Michigan (July 2018) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it has received FDA 510(k) clearance for its NeuMoDx™ 288 Molecular System and its NeuMoDx™ GBS Assay. The fully automated NeuMoDx™ 288 Molecular System is the first offering in a family of scalable platforms that integrate...
QIAGEN to launch two Sample to Insight systems in Europe and other markets, NeuMoDx™ to commercialize in the U.S. / Initial assay menu for infectious diseases and LDTs Hilden, Germany, and Ann Arbor, Michigan, September 17, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx™ Molecular, Inc. today announced a strategic partnership to...
